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Abstract Array based comparative genomic hybridisation
(aCGH) is a powerful technique for detecting clinically rel-
evant genome imbalance and can offer 40 to > 1000 times
the resolution of karyotyping. Indeed, idiopathic learning
disability (ILD) studies suggest that a genome-wide aCGH
approach makes 10–15% more diagnoses involving genome
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implemented as a routine NHS service. One signiﬁcant
obstacle is the perception that the technology is prohibitively
expensive for most standard NHS clinical cytogenetics
laboratories. To address this, we investigated the cost-effec-
tiveness of aCGH versus standard cytogenetic analysis for
diagnosing idiopathic learning disability (ILD) in the NHS.
Cost data from four participating genetics centres were col-
lected and analysed. In a single test comparison, the average
cost of aCGH was £442 and the average cost of karyotyping
was £117 with array costs contributing most to the cost
difference. This difference was not a key barrier when the
context of follow up diagnostic tests was considered. Indeed,
in a hypothetical cohort of 100 ILD children, aCGH was
found to cost less per diagnosis (£3,118) than a karyotyping
and multi-telomere FISH approach (£4,957). We conclude
that testing for genomic imbalances in ILD using microarray
technology is likely to be cost-effective because long-term
savings can be made regardless of a positive (diagnosis) or
negative result. Earlier diagnoses save costs of additional
diagnostic tests. Negative results are cost-effective in mini-
mising follow-up test choice. The use of aCGH in routine
clinical practice warrants serious consideration by healthcare
providers.
Keywords Microarrays  Comparative genomic
hybridisation  Cost-effectiveness  Learning disability
Introduction
Learning disability (LD) is a common condition affecting
1–3%ofindividualsworldwide(Roeleveldet al.1997).Most
with moderate to severe LD (intelligence quotient (IQ) under
50) require life long support and half of those with mild LD
(IQ 50–70) are signiﬁcantly impaired throughout life
(Department of Health 2001;M e n c a p2001). Despite the
clinical, social and psychological challenges associated with
LD, up to 80% of cases have no speciﬁc causal diagnosis.
Standard testing to detect constitutional anomalies
(present at or before birth) is chromosome analysis
(karyotyping) at the 450–500 G-band level. Karyotyping
can detect large genomic imbalances (losses or gains of
DNA) in LD conditions such as Down, Turner and Edwards
Syndromes. However, the resolution is insufﬁcient to rou-
tinely detect rearrangements smaller than 5 million base
pairs (5 Mb) and even abnormalities of 15 Mb may be
missed where the banding pattern is indistinct.
As smaller genomic imbalances can be clinically impor-
tant, demand has increased for higher resolution assays to
detect them. This is particularly true for idiopathic (without
known cause) LD (ILD) cases, that represent ~15% of refer-
rals to clinical genetics and paediatrics clinics. Despite ILD
being incurable, a diagnosis is important for many reasons
including, providing accurate prognostic information and
genetic counselling, directing appropriate clinical care and
educational needs, considering future preventative and ther-
apeutic regimes and ﬁnally helping clinicians to answer the
parents’question‘‘why?’’.Theclariﬁcationofgeneticriskfor
boththeimmediateandwiderfamilyisparticularlyimportant
because it enables meaningful reproductive choice. For
example, a negative result can substantially reduce risk
whereas a positive result can open an avenue for prenatal
diagnosis (in appropriate cases).
A major advance in diagnosing ILD through genetics was
the discovery that cytogenetically invisible genome imbal-
ances involving chromosome tips (telomeres) account for
many ILD cases (Flint et al. 1995). Subsequently, a test
assaying every telomere of an individual by ﬂuorescence
‘in situ’ hybridisation to chromosomes (‘multi-telomere
FISH’) was developed and widely adopted in diagnostic
laboratories (Knight et al. 1997). Further technological
advances led to a new approach, array comparative genome
hybridisation (aCGH), that identiﬁes cryptic genome imbal-
ances at the genome-wide level (Knight and Regan 2006).
Microarrays have received considerable attention in the
scientiﬁc research community. An array (microarray or
chip) is a solid surface, often a microscope slide, onto
which control DNA, cDNA (complementary DNA) or short
single stranded sequences (oligonucleotides) are spotted
(Aitman 2001). In aCGH, an array is used to compare a
control versus a test genome searching for differences in
the test genome (Fig. 1). When the test genome is a patient
DNA sample, such differences signpost DNA sequences
that might be implicated in the patient’s phenotype.
aCGH has application in many genetic conditions, proving
particularly useful in diagnosing ILD. Indeed, research
indicates that at least 10–15% more diagnoses are made
compared with standard cytogenetic analysis (Knight et al.
2006).
Despite this, aCGH is not implemented widely in the
NHS. One obstacle is the lack of consensus regarding
‘platform choice’, that is, the best combination of array
type, experimental methodology and analysis system.
Another obstacle is concern over the proportion of con-
ﬁrmed genome imbalances where the signiﬁcance of the
positive result is unknown e.g. very small ‘de novo’
imbalances and some inherited imbalances. However, the
most signiﬁcant obstacle to date is the perception that the
technology is prohibitively expensive for most NHS clin-
ical cytogenetics laboratories. Local commissioners are
unable to endorse implementation without considering the
clinical utility and economic implications of technology
adoption. Whilst the clinical and scientiﬁc utility of aCGH
in ILD is impressive, information on its economic viability
in routine clinical practice is lacking. Therefore, our study
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123aimed to estimate the cost-effectiveness of aCGH com-
pared with standard cytogenetic analysis in ILD.
Methods
Cost-effectiveness analysis
The costs and effects (number of additional diagnoses) of
an aCGH test versus standard cytogenetic analysis using
karyotyping, were compared. A cost per diagnosis detected
was used rather than a cost per life year gained or quality
adjusted life year (QALY), as testing is unlikely to save
lives and evaluating QALY’s is problematic in children,
especially those with LD.
An NHS perspective was adopted and to make the
results generally applicable to UK laboratories, four
laboratories currently investigating ILD using aCGH,
karyotyping or both contributed to data collection: (i) The
Wellcome Trust Centre for Human Genetics, University of
Oxford (arrays), (ii) Oxford Regional Cytogenetics Labo-
ratory (karyotyping), (iii) Birmingham Regional Genetics
Laboratory (arrays and karyotyping) and (iv) South East
Scotland Cytogenetics Laboratory, Edinburgh (arrays).
These were selected because they employ slightly different
testing procedures (e.g. different staff grades or level of
automation).
Testing pathways and resource use
This information was obtained through laboratories com-
pleting cost questionnaires (available from authors). Detailed
information, from a blood sample arriving at the laboratory
through to result reporting was collected (Figs. 2, 3).
Resource information on staff times, consumables and
capital was derived from the questionnaires. Salary costs
were attached to these based on NHS Agenda for Change
ﬁgures (Department of Health 2005) and unit costs were
attached to equipment and resource information from lab-
oratory price lists including 17.5% VAT, with maintenance
and service costs being included under the equipment
warranty. For capital items (e.g. array scanners), the cost
was spread over the items predicted lifetime and depreci-
ated using equivalent annual costing, discounted at 3.5%
(Drummond et al. 2005; HM Treasury 2006). Overheads,
including electricity were calculated as a percentage of
total costs (around 20%).
The costs of routine cytogenetics analysis include
karyotype analysis (see http://www.oup.co.uk/pdf/pas/
12–7–1.pdf for standard protocol). Array costs were based
on Agilent Technologies Inc. 4 · 44 K genome-wide
oligonucleotide multi-sample format arrays, with four dif-
ferent patient DNAs per slide (see www.chem.agilent.com/
temp/radAAF6F/00060479.pdf for protocols).
Testing scenarios
Most cases require additional tests to establish the clinical
relevance of a putative genomic imbalance identiﬁed by an
initial aCGH test. This is because a positive aCGH result
may be due to several reasons including:
(i) Imbalance is real and clinically relevant; without a po-
sitive family history, this would generally be expected
to be ‘de novo’ (absent in clinically normal parents) and
may or may not have been reported before in similarly
affected individuals. However, the imbalance may
also be inherited from a clinically normal parent, the
phenotype due to a recessive condition, incomplete
penetrance or genomic imprinting, for example.
Fig. 1 Overview of aCGH protocol (reproduced from Knight and
Regan (2006) with permission from S. Karger and AG. Basel)
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123(ii) Imbalance is real, but not clinically relevant; it may
be a benign polymorphism inherited from a clinically
normal parent or a ‘de novo’ benign variant that may
or may not have been reported before.
(iii) Imbalance is not real; it is a false positive that a
different test fails to conﬁrm.
By contrast, additional tests undertaken after karyotyp-
ing are most often to ﬁnd a diagnosis, rather than to
understand the clinical relevance of an abnormality.
Several testing and reporting scenarios were identiﬁed.
For arrays, additional tests such as testing parents using
arrays or FISH were included. For karyotyping, testing par-
ents and using feasible follow-up tests of multi-telomere
FISH and multi-telomere MLPA, were costed. Expert opin-
ion (Laboratory Directors) and laboratory records developed
these scenarios. Average test throughput was determined by
annual laboratory ﬁgures, equipment and staff availability.
Additional targeted tests e.g. those for speciﬁc gene muta-
tions and biochemical tests were not costed, as they apply to
both karyotyping and aCGH approaches when negative.
Sensitivity analysis
This explored the impact that changing individual costs has
on total costs. The costs varied included: arrays and
scanner, percentage used to calculate overheads, array
labelling, different staff grades, karyotyping probe costs
and test throughput. Ranges were based on expert opinion.
Data analyses were conducted in Microsoft Excel 2003 and
costs reported in Pounds sterling (£), using 2006 prices. As
costs were derived from different laboratories, the results
presented are averages of the four laboratories.
To create a cost per diagnosis, cost data were combined
with information on the predicted number of diagnoses for
100 hypothetical ILD cases referred via genetics clinics for
genomic imbalance testing. Costs were assigned to the
karyotyping route (factoring in one additional genome
imbalance test, a telomere assay, for karyotypically normal
samples) and for aCGH (where few, if any, additional
genome imbalance tests are required). The number of
diagnoses expected and the testing scenarios were derived
from clinical diagnostic laboratory records (karyotyping),
research experience (testing scenarios and 44 K aCGH
results to date) and published data (karyotyping, subtelo-
meric studies and aCGH ILD studies) (de Vries et al. 2005;
Knight 2005; Knight and Regan 2006; Menten et al. 2006;
Miyake et al. 2006; Rauch et al. 2006; Ravnan et al. 2006;
Rosenberg et al. 2005; Schoumans et al. 2005; Shaw-
Smith et al. 2004; Tyson et al. 2005; Vissers et al. 2003).
Results
Table 1 presents staff time and costs for a single aCGH and
karyotypetest.ForaCGH,theaveragestafftimepersampleis
142 min, at an average sample cost of £42 (range £36–£48).
Forkaryotyping,theaveragestafftimepersampleis210 min,
at an average sample cost of £85 (range £73–£96).
Table 2 presents the costs for a straightforward aCGH
test (no sample quality or quantity issues). The total cost of
£442 is the baseline cost excluding reporting or any other
investigations. Array slides account for 42% of total test
cost. Table 3 shows the costs for each testing stage when a
single karyotype is performed. The total cost is £117 (range
£103–£131), 73% of which is stafﬁng.
Karyotyping costs associated with different testing
and reporting scenarios
Table 3 presents a breakdown of the typical cost of karyo-
typing. Table 4 shows the cost differences associated with
Sample Reception and 
Initial Processing
Enzymatic digestion 
and clean-up 
Labelling with
Fluorochromes
Array Preparation,
Hybridisation and 
Washing 
Scanning
Analysis and 
Report Writing 
Fig. 2 Array-CGH testing
process
Sample Reception and 
Initial Processing
Media Preparation / 
Setting Up Culture 
Slide-making  Banding Analysis Results Reported
Synchronisation / 
Harvesting Culture 
Fig. 3 Karyotyping testing
process
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123different karyotype reporting scenarios and the costs of one
further test, a test of subtelomeric integrity either by FISH or
by MLPA, that may be requested following a negative
karyotyping result. Note that the identiﬁcation of an abnor-
mality with unknown clinical relevance always requires an
additional parental testing stage to help delineate pathogenic
from non-pathogenic anomalies. The cheapest scenarios, 1
and 2, are where genome imbalances already known to be
clinically benign or clinically relevant are found (£117). In
cases where an anomaly is ‘de novo’, the cheapest scenario
is Scenario 3: here, the genome imbalance is cytogenetically
visible, but of unknown clinical relevance and parental
samples are karyotyped to determine whether the anomaly is
benign or inherited (£351). For cases where the initial
karyotyping result is ‘normal’ and an additional assay of
telomere integrity reveals a clinically relevant (or clinically
benign) genome imbalance, the most expensive testing
scenario is Scenario 7 (£724); here a multi-telomere FISH
test is employed and follow-up tests of parental samples are
performed using targeted FISH. In the directly comparable
scenario (Scenario 6) where multi-telomere MLPA is used
for the patient and parental testing and targeted FISH for
patient conﬁrmation, the cost is £472. The most common
outcome of karyotyping plus an additional multi-telomere
assay testing is a negative result i.e. no genome imbalance is
found. In this case, Scenario 4 (multi-telomere MLPA), is
signiﬁcantly cheaper than Scenario 5 (Multi-telomere
FISH), with tests costs of £162 and £400 respectively.
Table 1 Staff costs for aCGH and Karyotyping
Medical technical
ofﬁcer
Clinical scientist Consultant grade
scientist
Secretarial staff Total time
Array CGH
Cost per hour range (£.p)
a 13.01–16.83 18.34–24.71 40.17–49.73 N/A N/A
Median cost per hour (£.p) 14.69 21.65 44.09 N/A N/A
Hands-on time (minutes) 61.00 76.00 5.00 N/A 142.00
Cost per sample range (£.p) 9.67–12.51 23.45–31.44 3.35–4.14 N/A 36.47–48.09
Cost per sample (£.p)
b 10.92 27.55 3.67 N/A 42.14
Karyotyping
Cost per hour range (£.p)
a 15.46–19.35 23.00–24.56 43.78–44.40 12.98 N/A
Hands-on time range (minutes) 40 –113 5–192 10–45 0–15 178–242
c
Hands-on time mid-point (minutes) 76.50 98.50 27.50 7.50 210.00
Cost per sample range (£.p) 10.31–34.51 1.92–78.71 7.05–33.30 0.00–3.24 73–96
c
Median Cost per sample (£.p)
b 22.41 40.32 20.18 1.62 84.53
a Includes superannuation and national insurance
b Cost per sample does not always equal cost per hour multiplied by time spent on one test due to batching
c The time ranges are based on several different labs, hence the ‘minimums’ are not all referring to the same lab, nor are all the ‘maximums’.
The lab with the shortest process, for example, used 113 min of MTO time, 5 min of Clinical Scientist time, 45 min of Consultant Grade
Scientist time, and 15 min of Secretarial time, making 178 min in total. The cost per sample range is calculated in a similar manner
Table 2 Array CGH cost breakdown
Stage
a Cost
Sample reception and initial processing £45
Digestion/Reference Sample Processing £15
Cleaning £4
Labelling £78
Arrays, plus preparation and washing
b £188
Scanning £14
Analysis and report writing £24
General resources (e.g. PC and printer) £1
Overheads £73
Total
c £442
a Cost of obtaining blood sample not included
b Cost of array: £500 for four patients, £125 each
c Baseline of 25 tests per week (1,150 per annum)
Table 3 Karyotyping cost breakdown
Stage
a Cost Range
Sample reception and initial processing £4.53 £4.48–£4.58
Media preparation/setting up culture £2.39 £1.62–£3.16
Synchronisation/harvesting culture £3.81 £2.93–£4.69
Slide-making £1.93 £1.05–£2.81
Banding £3.36 £2.28–£4.45
Analysis and checking £47.11 £39.15–£55.08
Reporting results and authorisation £29.39 £27.94–£30.84
Clinical liaison £1.27 £0.37–£2.18
General resources (e.g. PC and printer) £2.00 £2.00–£2.00
Overheads £21.29 £21.28–£21.30
Total
b £117 £103–£131
a Cost of obtaining blood sample not included
b Baseline of 61 tests per week (2,800 per annum)
Genomic Med. (2007) 1:35–45 39
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123aCGH costs associated with different testing and
reporting scenarios
When an initial aCGH test reveals a putative genomic
imbalance, additional tests are needed to help establish the
clinical relevance. Table 5 shows a number of possible
testing scenarios and associated costs (the baseline cost of
£442 derived in Table 2 differs from that given in the
Table 5 scenarios by £4–£16 due to different staff report-
ing times). The cheapest scenarios, 1 and 2, are where
genome imbalances already known to be clinically benign
or clinically relevant are found (£446). In cases where an
anomaly is ‘de novo’ and therefore more likely to be
clinically relevant, the cheapest scenario is Scenario 3: here
targeted FISH tests on the patient and parental samples are
performed (£672). In the case of ‘de novo’ duplications that
cannot be seen by FISH, then the cheapest scenario is
Scenario 5: here, an initial FISH test reveals that the
duplication is not visible by FISH and therefore targeted
patient and parental MLPA tests (that can detect duplica-
tions) are performed (£858). Importantly, FISH is the
cheapest follow-up test approach for all patients revealing a
putative genome imbalance by aCGH because for non-
commercially available probes, a single targeted FISH test
is less expensive than a single targeted MLPA test. In
addition, the working resolution of the 44 K arrays is
sufﬁcient to allow conﬁrmatory FISH tests. By means of
contrast, the most expensive scenarios, 6 (£1,232) and 7
(£1,358), both arise when the initial patient aCGH test
reveals an imbalance of unknown clinical relevance and the
follow-up testing strategy involves aCGH testing of
parental samples.
Sensitivity analysis
For karyotyping, staff time required to perform the test or
grade of staff used was the area most likely to impact upon
total costs. For instance, substituting a clinical scientist
with an MTO reduced the total cost to £95, a difference of
£22. Other costs had limited impact upon karyotyping total
costs. For aCGH, varying array (slide) costs had the
greatest impact upon total cost. Changing the array to £25
per patient, reduced total test cost to £342. By comparison,
equipment and staff costs had limited impact.
Comparing the costs of aCGH versus standard
karyotyping
Table 6 directly compares aCGH with karyotyping by
resource category. The basic total cost difference is £325,
with array costs accounting for the largest cost difference
between tests. By contrast, karyotyping is more labour
intensive, with staff costs almost double those of array
testing. Overheads for aCGH are higher as they are
calculated as a percentage of overall costs (~20%). Finally,
there is little difference in equipment costs; even the cost of
the array scanner (average £40,000) calculated over its
predicted life and divided by test throughput, is small.
Figure 4 shows an example of the testing pathways,
predicted number of diagnoses and associated cost
implications of testing the same 100 ILD genetics clinic
referrals for genomic imbalance via the routine karyotyping
route (factoring in one additionaltest, either a multi-telomere
FISH test or a multi-telomere MLPA test, for karyotypically
normal samples) and via the most cost-effective aCGH route.
For both approaches, most results are negative; there is
no diagnosis in 92% of cases using karyotyping and multi-
telomere tests and none in 82% of cases using aCGH. Inter-
estingly, the cost of karyotyping plus one multi-telomere
FISH test (£400) is comparable to a single 44 K aCGH test
where no putative abnormality is found (£442).
For positive results (diagnoses), Fig. 4 shows that with
karyotyping and multi-telomere testing, 8/100 diagnoses
are expected, costing £39,652 using multi-telomere FISH
and £17,032 using multi-telomere MLPA. With aCGH, the
most conservative estimate of at least 18 diagnoses is used
(10% more than the karyotyping route). Here, the least
expensive testing strategy (aCGH followed by patient tar-
geted FISH and parental targeted FISH or targeted MLPA)
gives an overall cost of £56,130. Thus, karyotyping with
just one additional test of multi-telomere FISH equates to
spending £4,957 to obtain a single diagnosis with 92%
cases requiring further tests to reach a diagnosis at a later
stage. Using multi-telomere MLPA the ﬁgure is reduced to
£2,129 per diagnosis, again with 92% cases requiring fur-
ther tests to reach a diagnosis. By contrast, the aCGH route
equates to £3,118 per single diagnosis (assuming 10%
more diagnoses than karyotyping plus multi-telomere
testing combined), with no further tests for genomic
imbalance required. This reduces to £2,440 per diagnosis if
the diagnostic yield of aCGH is 15% more than karyo-
typing plus multi-telomere testing.
Discussion
This paper has reported a cost-effectiveness analysis
comparing aCGH with karyotyping for detecting genomic
imbalances that diagnose ILD. The average cost of aCGH
was £442 per single (patient) sample and the average cost
of karyotyping was £117 per sample. The majority of the
cost-difference was accounted for by the array cost. Thus,
from a single test perspective, aCGH is more expensive
than karyotyping, explaining, in part, the hesitation by
Genomic Med. (2007) 1:35–45 41
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123commissioners to fund aCGH in NHS diagnostic labora-
tories.
In reality, the situation is more complex because infor-
mation regarding subsequent tests for genomic imbalance
must be considered before the true cost-effectiveness can
emerge.Wehaveshownthattheoverallcostperdiagnosisof
the karyotyping route, including a single multi-telomere
FISH assay (£4,957) is more expensive than that of the
aCGH route (£3,118) that yields 10% more diagnoses.
However, if the less conservative yield of 15% more diag-
noses is correct, then the aCGH cost reduces to £2,440 per
diagnosis, a ﬁgure more comparable to karyotyping plus the
alternative multi-telomere assay, MLPA (£2,129 per diag-
nosis).Importantly,92%ofcasestestedbykaryotypinganda
multi-telomereassaywillrequirefurthertestsforaneventual
diagnosis. By contrast, the aCGH route, which effectively
represents karyotyping, multi-telomere testing and not one,
but ~34,000 interstitial FISH tests as well as assaying the
entire human genome at higher resolution is unlikely to
require further genome-wide tests for genome imbalance.
Stand-alone karyotyping is the cheapest test when con-
sidered per diagnosis (£2,067), but this is at the sacriﬁce of
missing ~75% (12/18) diagnoses achievable by aCGH
(Fig. 4). Thus, the crux of the aCGH versus karyotyping
argument in ILD comes down to diagnostic capability
versus cost; how much is it acceptable to spend and how
many diagnoses is it acceptable to miss? aCGH clearly
offers the greatest diagnostic capability, providing 10–15%
more diagnoses over all other available tests.
One limitation of our study is that we do not know the
full magnitude of the cost for additional follow-up tests
after karyotyping. However, we do know that such costs
would rapidly escalate and even then the majority of
Table 6 Cost comparison of aCGH and karyotyping per sample
Cost category ACGH Karyotyping Cost difference
Staff £42 £85 –£43
Equipment £15 £3 +£12
Consumables £275 £6 +£269
Overheads £74 £21 +£53
Other costs £36 £2 +£34
Total £442 £117 £325
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Fig. 4 Flowchart example of the testing pathways, predicted
number of diagnoses and associated cost implications of testing
the same 100 ILD genetics clinic referrals for genome imbalance via
the routine karyotyping route (factoring in FISH and MLPA based
telomere tests, for karyotypically normal samples) and via the aCGH
route. The numbers of diagnoses expected via the karyotyping and
aCGH routes and the testing scenarios are derived directly from
published data, clinical diagnostic laboratory records and our own
research experience. The aCGH route is expected to yield 10–15%
more diagnoses than the karyotyping and multi-telomere testing
route. The costings given in the ﬂowchart are based on the
conservative estimate of 10% more diagnoses, but an overall cost
per diagnosis is calculated both for 10% and 15% more diagnostic
yields
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123diagnoses achievable by aCGH would be missed; clinically
relevant genomic imbalances found by genome-wide
aCGH are rarely recurrent and therefore targeted ap-
proaches are unlikely to improve diagnostic yield (Veltman
and de Vries 2006). Even if multi-telomere FISH or multi-
telomere MLPA are not the tests chosen following karyo-
typing, costing in only ﬁve targeted tests for genomic
imbalance at £100/test for every sample with a normal
karyotype would raise the overall cost of testing 100 pa-
tients to ~£59,402 (compared with £56,130 for aCGH) and
offer negligible improvement in resolution overall. Thus,
even without precise costing of follow-up tests, our results
suggest that aCGH is the most cost-effective testing strat-
egy in the long-term for testing ILD patients.
A further study limitation is the use of a simple outcome
measure, diagnosis, rather than the more usual cost per
quality adjusted life year promoted by the National
Institute for Health and Clinical Excellence. However,
describing and valuing health states in children is difﬁ-
cult and well documented (Petrou 2003). Current
methodological work in health economics may give use-
able health states for children, but is unlikely to be suited
for those with LD.
In this study, one scenario that we were unable to cost
either for karyotyping or array CGH was that of further
researching apparently inherited genome imbalances for
which clinical relevance cannot be excluded. Such cases
may reﬂect benign variants or may cause disease through
unmasking recessive mutations, through variable pene-
trance or through imprinting, for example. Currently these
account for up to 32% cases (see Fig. 4) and therefore
follow-up tests such as sequencing would be prohibitively
expensive (not all inherited imbalances are small). How-
ever, as more and more studies are performed and more
data regarding benign/relevant genome imbalances and
genotype/phenotype correlations are added to databases, it
is anticipated that the clinical relevance of a signiﬁcant
number of these cases will be deﬁned earlier, thereby
minimising the need for parental testing or additional fol-
low up tests. This in turn will lead to reduced aCGH testing
costs and costs arising from doctor/counsellor time taken to
discuss uncertain results. Furthermore, it may become
possible to reduce costs more by employing better deﬁned
clinical ‘gatekeeping’ criteria to help clinical geneticists
direct testing (thereby minimising total tests done). Data-
bases such as The Database of Genomic Variants (http://
projects.tcag.ca/variation/), The Human Structural Varia-
tion database, (http://humanparalogy.gs.washington.edu/
structuralvariation/), ECARUCA (http://agserver01.azn.nl:
8080/ecaruca/ecaruca.jsp) and the DatabasE of Chromo-
somal Imbalance and Phenotype in Humans using Ensembl
Resources (DECIPHER http://www.sanger.ac.uk/PostGe-
nomics/decipher/) have all been designed to expedite these
processes. Another possibility may be to use targeted
arrays as an initial screening test for paediatrician referrals,
though currently these offer no cost advantage over gen-
ome-wide arrays and utility will depend on a high diag-
nostic pick-up rate.
In the meantime, it will continue to be important for
families to be counselled in possible outcomes before
taking up the test, for both parental samples to be available
for testing and for any outgoing laboratory reports to be
carefully designed with clearly deﬁned results e.g. array
batch, controls used, imbalances found, conﬁrmatory
method and database search results that might help inform
clinical relevance.
In conclusion, our study demonstrates that in the context
of ILD, genome-wide aCGH is viable for NHS diagnostic
use. Indeed, where possible, it may be appropriate to
replace karyotyping with aCGH as the ﬁrst-line test for
genomic imbalance in ILD. If needed, samples that are
normal by aCGH could then be karyotyped in order to
identify truly balanced rearrangements or further
characterise genome imbalances. Additionally, aCGH is
expected to be useful for clarifying previous equivocal
karyotyping results (e.g. enabling deﬁnition of a cryptic
translocation in a family where only one of two unbalanced
outcomes is cytogenetically visible).
In the future, improved diagnostic yields of aCGH and
reduced follow-up tests will lower the costs of clinical
follow-up and additional investigations. Advances in
technology will also reduce costs (e.g. automation, in-
creased probe density, multi-sample and cheaper array
production and hybridisation methods) and software
improvements may reduce analysis time.
Finally, it is important to note that potential applications
of microarray technology extend beyond the genetic diag-
nosis of ILD to include a range of other conditions with
suspected genome imbalance and/or aberrant gene
expression e.g. haematological malignancies, colorectal
cancer and other ﬁelds including oncology, immunology,
neurology and pathology. The UK Department of Health is
keen for the NHS to adopt new technologies (Department
of Health 2003), yet commissioners are unable to endorse
implementation without considering the clinical utility and
economic implications of technology adoption. Our cost-
ing, with the results divided into different testing stages
provides a framework for costing array implementation in
different settings. Not least, it is intended that the study will
be useful for healthcare providers faced with the decision
of introducing aCGH testing into NHS laboratories before
the availability of substantial effectiveness information.
Acknowledgements The authors are grateful for ﬁnancial support
from the Oxford Genetics Knowledge Park (Dept of Health and Dept
of Trade and Industry: RR, SK and JT). SW is supported by a UK
44 Genomic Med. (2007) 1:35–45
123Department of Health Fellowship. We acknowledge support from the
UK Microarray Working Party, especially Hilary Burton, John Barber
and Phillipa Brice.
References
Aitman (2001) Science, medicine, and the future: DNA microarrays
in medical practice. BMJ 323:611–615
de Vries B, Pfundt R, Leisink M, Koolen D et al. (2005) Diagnostic
genome proﬁling in mental retardation. Am J Hum Genet
77:606–616
Department of Health (2001) A new strategy for learning disability
for the 21st Century. (http://www.archive.ofﬁcial-documents.
co.uk/document/cm50/5086/5086.pdf)
Department of Health (2003) Genetics white paper: our inheritance,
our future–realising the potential of genetics in the NHS. (http://
www.dh.gov.uk/PublicationsAndStatistics/Publications/Publica-
tionsPolicyAndGuidance/PublicationsPolicyAndGuidanceArti-
cle/fs/en?CONTENT_ID = 4006538&chk = enskFb)
Department of Health (2005) NHS reference costs. (www.doh.gov.uk/
nhsexec/refcosts.htm)
Drummond M, Sculpher M, Torrance G, O’Brien B et al. (2005)
Methods for the economic evaluation of health care programmes.
Oxford University Press, Oxford
Flint J, Wilkie A, Buckle V, Winter R et al. (1995) The detection of
subtelomeric chromosomal rearrangements in idiopathic mental
retardation. Nat Genet 9:132–140
HM Treasury (2006) Green book, appraisal and evaluation in central
government. (http://greenbook.treasury.gov.uk/)
Knight S (2005) Subtelomeric rearrangements in unexplained men-
tal retardation. In: Fuchs P (eds) Encyclopedia of medical
genomics and proteomics. Marcel Dekker Inc, New York,
pp 1246–1252
Knight S, Horsley S, Regan R, Lawrie N et al (1997) Development
and clinical application of an innovative ﬂuorescence in situ
hybridisation technique which detects submicroscopic rearrange-
ments involving telomeres. Eur J Hum Gen 5:1–8
Knight S, Regan R (2006) Idiopathic learning disability and genome
imbalance. Cytogen Gen Res 115:215–224
Mencap (2001) No ordinary life: The support needs for families
caring for children and adults with profound and multiple
learning difﬁculties. (http://www.mencap.org.uk/download/
no_ordinary_life.pdf)
Menten B, Maas N, Thienpont B, Buysse K et al (2006) Emerging
patterns of cryptic chromosomal imbalances in patients with
idiopathic mental retardation and multiple congenital anomalies:
a new series of 140 patients and review of the literature. Dig J
Med Genet: doi:10.1136/jmg.2005.039453 (http://jmg.bmj.com/
cgi/rapidpdf/jmg.032005.039453v039451)
Miyake N, Shimokawa O, Harada N, Sosonkina N et al (2006) BAC
array CGH reveals genomic aberrations in idiopathic mental
retardation. Am J Med Genet Part A 140A:205–211
Petrou S (2003) Methodological issues raised by preference-based
approaches to measuring the health status of children. Health
Eco 12:697–702
Rauch A, Hoyer J, Guth S, Zweier C et al (2006) Diagnostic yield of
various genetic approaches in patients with unexplained devel-
opmental delay or mental retardation. Am J Med Genet Part A
140A:2063–2074
Ravnan JB, Tepperberg JH, Papenhausen P, Lamb AN et al (2006)
Subtelomere FISH analysis of 11,688 cases: an evaluation of
the frequency and pattern of subtelomere rearrangements in
individuals with developmental disabilities. J Med Genet 43:
478–489
Roeleveld N, Zielhuis G, Gabreels F (1997) The prevalence of mental
retardation: a critical review of recent literature. Develop Med
Child Neurol 39:125–132
Rosenberg C, Knijnenburg J, Chauffaille M, Brunoni D et al (2005)
Array CGH detection of a cryptic deletion in a complex
chromosome rearrangement. Human Genet 116:390–394
Schoumans J, Ruivenkamp C, Holmberg E, Kyllerman M et al (2005)
Detection of chromosomal imbalances in children with idio-
pathic mental retardation by array based comparative genomic
hybridisation (array-CGH). J Med Genet 42:699–705
Shaw-Smith C, Redon R, Rickman L, Rio M et al (2004) Microarray
based comparative genomic hybridisation (array-CGH) detects
submicroscopic chromosomal deletions and duplications in
patients with learning disability/mental retardation and dysmor-
phic features. J Med Genet 41:241–248
Tyson C, Harvard C, Locker R, Friedman J et al (2005) Submicro-
scopic deletions and duplications in individuals with intellectual
disability detected by array-CGH. Am J Med Genet Part A
139A:173–185
Veltman J, de Vries B (2006) Diagnostic genome proﬁling:
unbiased whole genome or targeted analysis? J Mole Diag 8:
534–537
Vissers L, deVries B, Osoegawa K, Janssen I et al (2003) Array-based
comparative genomic hybridization for the genome-wide detec-
tion of submicroscopic chromosomal abnormalities. Am J
Human Genet 73:1261–1270
Genomic Med. (2007) 1:35–45 45
123